Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of “Moderate Buy” by Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $62.25.

Several analysts recently weighed in on the stock. Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price for the company. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $27.01 on Friday. The firm has a 50-day simple moving average of $33.29 and a two-hundred day simple moving average of $35.72. The stock has a market cap of $1.79 billion, a PE ratio of -10.65 and a beta of 1.60. Celldex Therapeutics has a 1-year low of $24.43 and a 1-year high of $53.18.

Insider Buying and Selling

In other Celldex Therapeutics news, CEO Anthony S. Marucci bought 11,500 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average price of $26.82 per share, with a total value of $308,430.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Celldex Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD lifted its position in Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after acquiring an additional 2,664,915 shares during the last quarter. Novo Holdings A S acquired a new stake in shares of Celldex Therapeutics during the second quarter worth about $31,458,000. Point72 Asset Management L.P. lifted its holdings in shares of Celldex Therapeutics by 51.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock valued at $71,725,000 after purchasing an additional 654,194 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after purchasing an additional 604,251 shares during the period. Finally, Marshall Wace LLP boosted its position in shares of Celldex Therapeutics by 53.3% in the 2nd quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after purchasing an additional 479,068 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.